US Man Dies After Inhaler Price Spikes, Family Sues for Justice

A Life Cut Short by Healthcare Costs

Cole Schmidtknecht, a 22-year-old man working as a trucker in Wisconsin, had been managing his asthma since he was a child with the help of corticosteroid inhalers. These medications were essential to his survival. However, in late 2023, his insurance provider, OptumRx, abruptly removed his prescribed medication, Advair Diskus, from its covered drug list. Schmidtknecht’s situation took a devastating turn when he visited his local Walgreens pharmacy on January 10, 2024, only to discover that his insurance no longer covered the inhaler.

The price of the inhaler had skyrocketed to $539.19, a significant increase from the $35 to $66 Schmidtknecht had previously paid. Faced with limited financial resources and a modest hourly wage from his trucking job, Schmidtknecht had to make an impossible choice: pay for his medication or pay rent. He chose to prioritize rent and left the pharmacy without his essential medication, relying on an old inhaler that was not enough to manage his condition.

The Consequences of Inaccessibility

The consequences of Schmidtknecht’s decision were tragic. Over the next five days, his asthma worsened. On January 15, Schmidtknecht suffered a severe asthma attack, and his roommate rushed him to the hospital in Appleton, Wisconsin. Despite emergency efforts, including CPR and epinephrine injections, Schmidtknecht remained in a coma for six days. His family ultimately made the difficult decision to remove him from life support, and he was pronounced dead on January 21, 2024.

Schmidtknecht’s death has prompted his family to file a lawsuit against Walgreens and OptumRx. The lawsuit claims that the two companies are responsible for his death, as they allowed the price of the medication to soar, effectively denying Schmidtknecht access to the life-saving treatment he needed. The family argues that OptumRx’s decision to remove the inhaler from its formulary list was driven by profit motives, disregarding the health and well-being of vulnerable patients like Schmidtknecht.

The Role of Pharmacy Benefit Managers

At the heart of the lawsuit is the role of Pharmacy Benefit Managers (PBMs), such as OptumRx, which control access to medications and their pricing. PBMs are large, influential entities in the pharmaceutical industry that negotiate prices between drug manufacturers and insurance companies. However, critics argue that PBMs are contributing to rising healthcare costs by prioritizing profits over patient welfare.

UnitedHealth Group, which owns OptumRx, is one of the three largest PBMs in the U.S. The Schmidtknecht family’s lawsuit highlights the power these companies have over the accessibility and affordability of prescription medications. By removing essential medications from their covered lists and pushing patients toward more expensive alternatives, PBMs are accused of making life-saving treatments unaffordable for many individuals.

A Broken System: The Financial Strain of Healthcare

Schmidtknecht’s case is not an isolated one. Millions of Americans are struggling with the high cost of medications, especially for chronic conditions like asthma. The current healthcare system in the U.S. places a heavy financial burden on individuals who must choose between essential medications and basic living expenses. For many people, including Schmidtknecht, the decision to forgo medication leads to dire consequences.

In Schmidtknecht’s case, the $539.19 cost of the inhaler was simply out of reach. His modest income as a trucker left him with little room to spare for life-saving medication. With the pharmaceutical industry controlling the prices of essential drugs, many individuals are forced to make similar heartbreaking decisions. The Schmidtknecht family’s lawsuit is not just about seeking justice for one man’s death, but also about calling attention to the larger systemic issue of unaffordable healthcare in the United States.

The Legal Battle: Seeking Justice

The Schmidtknecht family’s lawsuit is a significant step in holding pharmaceutical companies accountable for their role in the rising costs of healthcare. The family is seeking damages for their son’s lost future earnings, suffering, and funeral expenses, as well as compensation for the emotional toll caused by his wrongful death. The lawsuit also includes a claim for “loss of society and companionship,” allowing the family to seek compensation for the emotional void left by their son’s death.

The outcome of this lawsuit could set a precedent for future cases involving the affordability of essential medications. By targeting both Walgreens and OptumRx, the Schmidtknecht family is shining a light on the policies and practices that contribute to the skyrocketing costs of healthcare. If successful, this lawsuit could prompt changes in how PBMs operate and how drug prices are determined, ultimately leading to greater transparency and accountability in the pharmaceutical industry.

The Bigger Picture: Pharmaceutical Pricing and Accessibility

Schmidtknecht’s tragic death is a stark reminder of the importance of affordable healthcare and access to life-saving medications. His family’s lawsuit is just one example of the growing movement to address the systemic issues within the U.S. healthcare system. With rising drug prices and the influence of PBMs, many Americans are left without the means to access the medications they need to survive.

As healthcare costs continue to rise, it is essential for lawmakers and industry leaders to address the root causes of this issue. In addition to holding pharmaceutical companies accountable, the U.S. must prioritize policies that make healthcare more affordable and accessible for everyone, regardless of income.

The Fight for Affordable Medication

The Schmidtknecht family’s legal battle is a reminder that access to healthcare is not just a matter of convenience—it is a matter of life and death. The story of Cole Schmidtknecht underscores the urgent need for reform in the U.S. healthcare system. It is time for lawmakers, pharmaceutical companies, and healthcare providers to work together to create a system that prioritizes the health and well-being of individuals over profits.

In the meantime, the Schmidtknecht family’s pursuit of justice continues. They hope that their lawsuit will not only bring accountability for their son’s death but also spark a broader conversation about the rising costs of healthcare and the need for change. As the legal proceedings unfold, Schmidtknecht’s tragic story will continue to serve as a reminder of the human cost of unaffordable medications.

The Ongoing Struggle for Healthcare Reform

The Schmidtknecht family’s fight for justice highlights a broader issue within the U.S. healthcare system: the unaffordable cost of prescription medications. With the financial burden of healthcare weighing heavily on individuals, it is essential that policymakers take action to ensure that life-saving treatments are accessible to everyone. The Schmidtknecht family’s lawsuit is just one example of the devastating consequences that can arise when healthcare costs become too high. As the fight for affordable healthcare continues, Schmidtknecht’s story serves as a tragic reminder of the need for reform.